Detailed explanation of how much does giritinib cost?

The highly potent and selective FLT3 kinase inhibitor Gilitinib is the first tyrosine kinase inhibitor approved as monotherapy for the treatment of relapsed and/or refractory FLT3-mutant acute myeloid leukemia (AML). Receptor tyrosine kinaseFLT3 is the most commonly mutated gene in acute myeloid leukemia. Giritinib has been shown to improve survival compared with salvage chemotherapy. Giritinib has a favorable toxicity profile when administered orally. Current clinical trials are also evaluating giritinib in combination with first-line chemotherapy, with other drugs such as venetoclax and azacitidine in patients who are not eligible for standard induction therapy, and as a maintenance agent.

The original drug of giritinib has been launched in China, sold under the name of giritinib fumarate tablets (XOSPATA). Currently, it has not been included in the scope of medical insurance reimbursement. The price of a common 40mg*42 tablet per box may be more than 20,000 RMB. The price of the Hong Kong version of the original drug is around 90,000 RMB per box. The price of the European version of the original drug, 40mg*84 tablets, per box sold overseas is around RMB 210,000 (the price may fluctuate due to exchange rate effects). For families with heavy financial burdens, the high price may increase their pressure.

Generic drugs of giritinib are currently produced and sold overseas. Its drug ingredients are basically the same as those of the original drugs sold domestically and abroad. Its price is cheaper than the original drugs. For example, the price of 40mg*84 tablets per box produced by a Laos pharmaceutical factory is more than 4,000 yuan (the price may fluctuate due to exchange rates). For more overseas drug information and specific prices, please consult Yaode Medical Consultant.